PYN Phynova

 

TIDMPYN 
 
RNS Number : 4518T 
Phynova Group PLC 
05 June 2009 
 
5 June 2009 
 
 
Phynova Group plc 
("Phynova" or the "Company") 
 
 
Board update and director's dealing 
 
 
Phynova (AIM: PYN), a leading botanical drug development company, today 
announces a restructuring of its board of directors, with immediate effect. The 
board changes are being made following the resignation of the Executive Chairman 
and a review of the business. 
 
 
Robert Miller, currently a director of the Company and Chief Executive Officer 
of Phynova China Limited, has been re-appointed Chief Executive Officer of the 
Company. In addition, Tony Mills, currently a director of the Company and Chief 
Executive Officer of Phynova Limited, has been appointed Chief Commercial 
Officer of the Company. Michael Martin will continue as part-time Chief 
Financial Officer. 
 
 
Following the changes set out above, the board will comprise Steve Harris 
(Non-Executive Chairman), Robert Miller (Chief Executive Officer), Dr Tony Mills 
(Chief Commercial Officer), Michael Martin (part-time Chief Financial Officer) 
and Dr Jin Li (Non-Executive Director). 
 
 
The Company also announces that Robert Miller has today gifted 383,333 ordinary 
shares, equivalent to 1.22 per cent. of the Company's issued share capital, to 
Ms Alice Lyon. Following the transfer of these shares, Mr Miller now holds 
745,853 ordinary shares, equivalent to 2.37 per cent. of the voting share 
capital. Ms Lyon does not have a notifiable interest in the Company. 
 
 
For further information, please contact: 
 
 
+-----------------------------------------------------+--------------------------+ 
| Phynova Group PLC                                   |      +44 (0) 1993 880700 | 
+-----------------------------------------------------+--------------------------+ 
| Steve Harris (Non-Executive Chairman)               |                          | 
+-----------------------------------------------------+--------------------------+ 
| Robert Miller (Chief Executive Officer)             |                          | 
+-----------------------------------------------------+--------------------------+ 
| Tony Mills (Chief Commercial Officer)               |                          | 
+-----------------------------------------------------+--------------------------+ 
|                                                     |                          | 
+-----------------------------------------------------+--------------------------+ 
|                                                     |                          | 
+-----------------------------------------------------+--------------------------+ 
| John East & Partners Limited                        |     +44 (0) 20 7628 2200 | 
+-----------------------------------------------------+--------------------------+ 
| John East/Simon Clements                            |                          | 
+-----------------------------------------------------+--------------------------+ 
|                                                     |                          | 
+-----------------------------------------------------+--------------------------+ 
 
 
Notes to Editors: 
 
 
About Phynova 
Phynova is a UK company developing new prescription pharmaceuticals derived from 
plants used in Chinese medicines. The Company is focused on viral and bacterial 
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C 
has now completed a Phase I/II trial in the US. One further product, for 
post-operative ileus, is targeted for entry to the clinic and there are a 
further four products in preclinical development. 
 
 
For further information please visit www.phynova.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 BOASSFFFISUSESM 
 

Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025

Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025